DocumentRX-9077
Issued
Read2 min

FDA issues warning letter for Alkem's Daman plant after OAI inspection

The US FDA issued a November 18, 2026 warning letter for Alkem's Amaliya, Daman plant after an April–May inspection classified OAI. Manufacturing and US supply continue; Alkem reports no material financial impact.

TAG V-2094 · 379 words on the filing

Alkem Laboratories receives US FDA warning letter for Daman facility - Business Upturn
Alkem Laboratories receives US FDA warning letter for Daman facility - Business UpturnHeungSoon / pixabay

Summary of findings

  • US FDA warning letter dated November 18, 2026 for Alkem's Amaliya, Daman facility
  • Inspection ran April 20–May 1, 2026 and was classified Official Action Indicated (OAI)
  • Alkem continues manufacturing and supplying approved products to the US from the site
  • Company must implement corrective and preventive actions and respond within the stipulated timeline
  • Alkem reports no material impact on financial, operational, or other activities

The US FDA has issued a formal warning letter, dated November 18, 2026, for Alkem Laboratories' manufacturing facility at Amaliya, Daman. The letter closes out an inspection that ran from April 20 to May 1, 2026, and which the agency had already classified as Official Action Indicated (OAI) — its most serious site-status rating, signalling significant regulatory or compliance problems.

Alkem disclosed the communication in a regulatory filing to the National Stock Exchange of India. The company must now implement corrective and preventive actions (CAPA, the structured remediation process companies file to fix root causes) to address the inspection observations and prevent their recurrence.

Does the plant keep supplying the US?

Yes. Despite the warning letter, Alkem continues manufacturing and supplying approved products to the US market from the Amaliya facility. A warning letter does not, by itself, trigger an import ban or suspension of drug approvals tied to the site. That's the key commercial fact here.

The company has committed to respond to the FDA within the stipulated timeline. Under agency procedures, warning-letter recipients typically get 15 working days to reply, and the clock started with the November 18 communication.

Alkem's read on the financial side is blunt. The filing states there is no material impact on the company's current financial, operational, or other activities from the letter.

What happens next?

The mechanics matter for anyone tracking the stock or the site's ANDA pipeline. An OAI classification plus a warning letter usually means:

  • New product approvals tied to the facility can stall until the FDA reclassifies the site
  • The company must complete CAPA and demonstrate sustained compliance, often through a re-inspection
  • Failure to resolve the issues can escalate to import alerts or, in extreme cases, consent decrees

For now, existing approved products keep flowing. The revenue risk sits in the approval queue, not the shipping dock.

The warning letter is the latest step in a documented chain: inspection April 20–May 1, 2026, OAI classification, then the November 18 letter. Each stage raised the stakes; this one puts the remediation burden formally on Alkem's shoulders.

Takeaway: Daman stays open and shipping, but the site's regulatory standing now depends entirely on how fast and how credibly Alkem executes its corrective plan.

via FDA industry wire (Google News) (Source)

Share this article:

More from Daniel Okafor

Daniel Okafor

Show full bio

Correspondent covering technology and product news in global pharmaceutical industry at PharmInsider.

11 articles

Linked filings

  1. E-9658
  2. E-9124
  3. P-4283
  4. P-1559
  5. E-4696

« Previous filingNext filing »